miR-944 inhibits malignant progression of bladder cancer through ATIC/AKT/FOXO3 A axis mediated by SHMT1

Zhiming Liu, Chen Zhao, Haibei Yang, Junning Liu, Maorong Cui, Weisheng Wang2025 · DOI

Abstract

Bladder cancer (BC) remains a significant clinical challenge due to its high recurrence and potential for metastasis. This study investigates the role of miR-944 in BC progression. Analysis of clinical samples and cell lines revealed that miR-944 is significantly downregulated in BC. Functional assays demonstrated that overexpressing miR-944 inhibits cell proliferation, migration, and invasion in vitro and suppresses tumor growth in vivo. Mechanistically, miR-944 targets SHMT1, which in turn regulates ATIC to modulate the AKT/FOXO3A signaling pathway. This axis influences autophagy and epithelial-mesenchymal transition (EMT), suggesting that miR-944 could serve as a novel therapeutic target for bladder cancer.

Introduction

Bladder cancer is characterized by a complex molecular landscape and a high propensity for recurrence. Despite advancements in surgical and adjuvant treatments, the prognosis for patients with advanced or metastatic disease remains poor. A critical area of research involves metabolic reprogramming, where cancer cells alter metabolic pathways to support rapid proliferation. MicroRNAs (miRNAs) have emerged as key regulators of these processes. This study focuses on miR-944 and its role in regulating one-carbon metabolism and purine synthesis through the SHMT1/ATIC axis.

Methodology

The researchers utilized a comprehensive experimental framework to validate their hypotheses:

  • Clinical Analysis: Twelve pairs of human BC tissues and adjacent paracancerous tissues were analyzed using RT-qPCR and Western blot to establish expression patterns of miR-944 and SHMT1.
  • Cellular Models: Multiple BC cell lines (RT-4, KK47, T24, 5637, HT-1376) were screened. The T24 line was selected for further functional studies due to its low endogenous miR-944 levels.
  • Molecular Interactions:
    • Dual-Luciferase Reporter Assay: Confirmed the direct binding of miR-944 to the SHMT1 gene.
  • Co-Immunoprecipitation (Co-IP): Identified physical interactions between SHMT1, ATIC, and AKT proteins.
  • Functional Assays: Cell viability was assessed via CCK-8, while migration and invasion were measured using scratch wound and Transwell assays. Autophagy was visualized using MDC labeling.
  • In Vivo Studies: T24 cells were subcutaneously injected into BALB/c nude mice to evaluate the impact of miR-944 on tumor growth in a physiological environment.

Key Insights: The SHMT1/ATIC/AKT Relay

The study identifies a novel metabolic-signaling relay that drives BC progression:

  1. Loss of miR-944: In BC, the downregulation of miR-944 removes the inhibitory control over SHMT1 (Serine Hydroxymethyltransferase 1).
  2. SHMT1-ATIC Interaction: Elevated SHMT1 levels facilitate an interaction with ATIC (5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase), a key enzyme in purine biosynthesis.
  3. AKT Pathway Activation: The SHMT1/ATIC complex activates the AKT/FOXO3A signaling pathway, which promotes cell survival and growth.
  4. Phenotypic Shift: This axis suppresses autophagy (reducing cell death) and promotes Epithelial-Mesenchymal Transition (EMT), allowing cells to detach and invade other tissues.

Results

  • Expression Profiles: miR-944 expression was markedly lower in BC tissues compared to healthy controls, while SHMT1 and ATIC proteins were overexpressed.
  • Tumor Suppression: Restoring miR-944 levels in T24 cells significantly reduced their proliferative and invasive capabilities. In the xenograft mouse model, miR-944 overexpression resulted in significantly smaller tumor volumes and weights.
  • Biomarker Changes: miR-944 upregulation led to an increase in the epithelial marker E-cadherin and a decrease in mesenchymal markers such as Vimentin and N-cadherin. Additionally, it promoted the expression of autophagy-related proteins LC3II/I and Beclin1.
  • Pathway Inhibition: miR-944 effectively inhibited the phosphorylation of AKT, thereby deactivating the downstream pro-cancer signaling.

Conclusion and Future Directions

This research confirms that miR-944 acts as a potent tumor suppressor in bladder cancer by targeting the SHMT1/ATIC/AKT/FOXO3A axis. While these findings are promising, several areas require further investigation:

  • Generalizability: Future studies should validate these mechanisms across a broader range of BC cell lines.
  • Regulatory Mechanisms: The factors leading to the initial downregulation of miR-944 in BC remain to be elucidated.
  • Clinical Translation: Transitioning from mouse models to human clinical trials is essential to determine the safety and efficacy of miR-944-based therapies.
  • Autophagy Dynamics: Given the dual role of autophagy in cancer, more detailed studies are needed to understand how miR-944-induced autophagy specifically contributes to tumor suppression.

Ultimately, the miR-944/SHMT1/ATIC axis represents a viable target for developing precision medicine strategies for bladder cancer patients.

Summary updated

Abstract

To investigate the role of miR-944 in the progression of bladder cancer (BC) and explore its potential as a therapeutic target. In this study, we collected 12 pairs of BC tissues and paracancerous tissues and subcutaneously injected T24 cells into BALB/c nude mice at 1 × 10<sup>6</sup>/mouse to establish the BC animal model for experimental investigation. RT-qPCR and western blot were used to detect the expression of related genes and proteins, and the malignant progression of T24 cells and BC was detected by CCK-8, Transwell, scratch wound, and immunohistochemistry. This study found that miR-944 expression was low in BC clinical samples and cell lines. Overexpression of miR-944 inhibited the proliferation, migration, and invasion of BC cells and inhibited BC tumor growth in vivo. Mechanistically, overexpression of miR-944 downregulated ATIC by inhibiting SHMT1, thereby activating the AKT/FOXO3A signaling pathway and promoting the expression of autophagy-related proteins LC3II/I and Beclin1. At the same time, it can inhibit the expression of epithelial-mesenchymal transition (EMT)-related proteins vimentin, fibronectin, and N-cadherin, ultimately inhibiting the proliferation, migration, and invasion of BC cells, and increasing the apoptosis level of BC cells to improve the development of BC. Our study confirmed that the upregulation of miR-944 may become a new target for the treatment of BC.
BibTeX
@inproceedings{liu2025mir,
  author = {Zhiming Liu and Chen Zhao and Haibei Yang and Junning Liu and Maorong Cui and Weisheng Wang},
  title = {{miR-944 inhibits malignant progression of bladder cancer through ATIC/AKT/FOXO3 A axis mediated by SHMT1}},
  booktitle = {In},
  year = {2025},
  doi = {10.1007/s11626-025-01050-1},
}
Figure